<DOC>
	<DOCNO>NCT00006386</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness radiation therapy follow carmustine treating patient supratentorial glioblastoma multiforme .</brief_summary>
	<brief_title>Radiation Therapy Followed Carmustine Treating Patients Who Have Supratentorial Glioblastoma Multiforme</brief_title>
	<detailed_description>OBJECTIVES : - Determine overall progression-free survival patient supratentorial glioblastoma multiforme treat accelerated radiotherapy conformal stereotactic radiotherapy boost follow carmustine . - Determine short long-term toxicity regimen patient . - Determine feasibility regimen patient . OUTLINE : Patients receive daily accelerate radiotherapy 5 day week week 1-2 . On week 3-6 , patient receive accelerate radiotherapy 4 day week ( 3 day week week 6 ) conformal stereotactic radiotherapy boost weekly . Patients receive carmustine IV 1-2 hour day 1-3 every 8 week 6 course begin within 1 month completion radiotherapy . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 76 patient accrue study within 15 month .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm supratentorial glioblastoma multiforme surgical biopsy resection within 5 week study Postoperative residual contrast enhance tumor resection tumor cavity together great 60 mm maximum diameter No welldifferentiated anaplastic astrocytomas multifocal glioma No tumor originate brainstem No residual tumor within 10 mm optic chiasm No recurrent glioblastoma multiforme PATIENT CHARACTERISTICS : Age : Not specify Performance status : Zubrod 01 Life expectancy : Not specify Hematopoietic : Hemoglobin great 9 g/dL Absolute neutrophil count great 1,500/mm^3 Platelet count great 100,000/mm^3 Hepatic : Bilirubin le 2.0 mg/dL Serum glutamate pyruvate transaminase ( SGPT ) serum glutamate oxaloacetate transaminase ( SGOT ) less 2 time normal Renal : Creatinine le 1.8 mg/dL Blood urea nitrogen ( BUN ) less 30 mg/dL Pulmonary : Chest xray normal OR Diffusion capacity lung carbon monoxide ( DLCO ) great 60 % predict Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Neurologic functional status 03 No prior malignancy within past 5 year except carcinoma situ cervix bladder , ductal carcinoma situ breast , nonmelanomatous skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Concurrent steroid allow Radiotherapy : Not specify Surgery : See Disease Characteristics Other : Concurrent anticonvulsant allow</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>